Americas Sleep Apnea Market Worth $4.10 Billion, Globally, by 2030 - Exclusive Report by The Insight Partners
November 10, 2023 05:46 ET
|
The Insight Partners
Pune, India, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Sleep apnea is a potentially serious sleep disorder where breathing repeatedly stops and starts. Such a condition prevents the patient's body from...
Global Sleep Apnea Market Analysis & Forecast to 2023-2033
November 08, 2023 04:08 ET
|
Research and Markets
Dublin, Nov. 08, 2023 (GLOBE NEWSWIRE) -- The "Global Sleep Apnea Market Analysis & Forecast to 2023-2033: Market By Product; By End-user; and by Region" report has been added to ...
Apnimed to Participate in Upcoming November Investor Conferences
November 06, 2023 08:00 ET
|
Apnimed, Inc.
CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...
Global Sleep Apnea Implants Market 2023-2027: Increasing Prevalence of Sleep Apnea and Respiratory Disorders Drives Growth
November 03, 2023 06:08 ET
|
Research and Markets
Dublin, Nov. 03, 2023 (GLOBE NEWSWIRE) -- The "Global Sleep Apnea Implants Market 2023-2027" report has been added to ResearchAndMarkets.com's offering.The sleep apnea implants market is forecasted...
Apnimed Announces Launch of Joint Venture with Shionogi to Develop Novel Pharmacologic Therapies for Obstructive Sleep Apnea and other Sleep Disorders
October 31, 2023 20:00 ET
|
Apnimed, Inc.
CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...
Apnimed to Present Review of Recent Data on Investigational Pharmacologic Treatment for Obstructive Sleep Apnea at World Sleep 2023
October 18, 2023 08:00 ET
|
Apnimed, Inc.
CAMBRIDGE, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea...
Apnimed to Participate in Upcoming October Investor Conferences
October 11, 2023 08:00 ET
|
Apnimed, Inc.
CAMBRIDGE, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...
American Journal of Respiratory and Critical Care Medicine Publishes Full, Positive Results of Apnimed’s MARIPOSA Study on AD109, an Investigational Oral Drug for Obstructive Sleep Apnea
October 10, 2023 08:30 ET
|
Apnimed, Inc.
CAMBRIDGE, Mass., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...
Apnimed Adds Independent Director Paul Fonteyne, MS, MBA to Board of Directors
October 02, 2023 08:00 ET
|
Apnimed, Inc.
Apnimed Adds Independent Director Paul Fonteyne, MS, MBA to Board of Directors
Global Sleep Apnea Diagnostic System Industry Research Report 2023-2030 - AI Innovations Transform Sleep Disorder Diagnosis in Booming Market
September 28, 2023 10:28 ET
|
Research and Markets
Dublin, Sept. 28, 2023 (GLOBE NEWSWIRE) -- The "Sleep Apnea Diagnostic System Market, By Product Type, By End User, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030"...